18,801 Dianthus Therapeutics, Inc. $DNTH Shares Acquired by Alps Advisors Inc.

Key Points

• Alps Advisors increased its Dianthus Therapeutics stake by 34% in the third quarter, buying 18,801 shares to hold 74,082 shares valued at about $6.5 million. Institutional investors collectively own 47.53% of the company.
• Analysts maintain a consensus Buy rating with an average price target of $128.77; recent targets range from $113 to $156.
• Dianthus reported a quarterly loss of $0.81 per share, narrower than analysts’ $0.94 estimate, and revenue of $1.21 million versus expectations of $0.46 million. Company insiders sold 45,902 shares worth about $4.8 million in the last quarter.

Alps Advisors Inc. boosted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 34.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,082 shares of the company's stock after purchasing an additional 18,801 shares during the quarter. Alps Advisors Inc. owned about 0.14% of Dianthus Therapeutics worth $6,523,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. First Horizon Corp acquired a new stake in shares of Dianthus Therapeutics during the 1st quarter worth about $32,000. EFG International AG bought a new position in Dianthus Therapeutics in the 2nd quarter valued at about $49,000. GAMMA Investing LLC raised its holdings in Dianthus Therapeutics by 83.6% in the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company's stock valued at $49,000 after acquiring an additional 254 shares during the period. Global Retirement Partners LLC bought a new position in Dianthus Therapeutics in the 2nd quarter valued at about $93,000. Finally, Nisa Investment Advisors LLC lifted its position in Dianthus Therapeutics by 75.0% during the third quarter. Nisa Investment Advisors LLC now owns 1,057 shares of the company's stock worth $93,000 after acquiring an additional 453 shares during the last quarter. 47.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DNTH. Roth Capital began coverage on Dianthus Therapeutics in a report on Tuesday, October 27th. They set a "buy" rating and a $113.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. JPMorgan Chase & Co. started coverage on Dianthus Therapeutics in a research note on Friday, September 11th. They set an "overweight" rating and a $135.00 target price on the stock. Citigroup initiated coverage on Dianthus Therapeutics in a report on Friday, September 4th. They set a "buy" rating and a $156.00 price target for the company. Finally, Truist Financial boosted their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics has a consensus rating of "Buy" and an average price target of $128.77.

Insiders Place Their Bets

In other news, EVP Simrat Randhawa sold 23,124 shares of Dianthus Therapeutics stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total value of $2,460,624.84. Following the completion of the sale, the executive vice president directly owned 4,000 shares in the company, valued at approximately $425,640. The trade was a 85.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Simon Read sold 2,778 shares of the business's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $117.55, for a total value of $326,553.90. Following the completion of the sale, the director owned 2,778 shares of the company's stock, valued at approximately $326,553.90. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,902 shares of company stock worth $4,814,779 in the last quarter. Corporate insiders own 3.02% of the company's stock.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH opened at $86.03 on Monday. Dianthus Therapeutics, Inc. has a 52 week low of $34.29 and a 52 week high of $117.88. The firm has a market cap of $4.71 billion, a price-to-earnings ratio of -21.56 and a beta of 1.47. The firm's 50-day simple moving average is $90.05 and its 200 day simple moving average is $85.57.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.13. The business had revenue of $1.21 million during the quarter, compared to analysts' expectations of $0.46 million. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 19.68%. Sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -3.60 EPS for the current year.

Dianthus Therapeutics Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company's research focuses on selectively targeting complement activity that contributes to disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.